Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Bead-Based Capture Kit Eases Enrichment and Cleanup of DNA Libraries

By BiotechDaily International staff writers
Posted on 13 Jun 2013
Print article
Image: The new SeqCap EZ Pure Capture Bead Kit (Photo courtesy of Roche Nimblegen).
Image: The new SeqCap EZ Pure Capture Bead Kit (Photo courtesy of Roche Nimblegen).
A newly released bead-based capture system was designed to provide genomic researchers with a sensitive and robust method for capture and purification of DNA sample libraries enabling high-quality targeted sequencing results.

NimbleGen (Madison, WI, USA), the genomics products subsidiary of Roche (Basel, Switzerland), recently announced the global launch of its SeqCap EZ Pure Capture Bead Kit.

This kit offers researchers a set of capture and purification beads used to prevent secondary capture and isolate DNA sample libraries from contaminants during amplification. It, therefore, represents a sensitive and robust method for cleanup of DNA sample libraries for high-quality DNA sequencing results


The kit includes SeqCap EZ Capture Beads and SeqCap EZ Purification Beads. Capture beads are used to recover the captured DNA sample from the hybridization of the DNA sample library and the SeqCap EZ Library. Purification beads are used to purify the amplified DNA sample library and the amplified capture DNA sample library after LM-PCR (ligase mediated - polymerase chain reaction). Roche provides a comprehensive set of reagents and probe pools for superior target enrichment performance. The probe pools include exome libraries, gene panels, and custom designs.

In addition to the SeqCap EZ Capture Beads Kit, Roche NimbleGen has released new disease-specific target enrichment panels for clinical research applications. These include the SeqCap EZ Comprehensive Cancer Design, which covers 578 genes implicated in a wide range of common and rare cancers, and the SeqCap EZ Neurology Panel Design, which covers 256 genes associated with 87 neurological disorders, including Parkinson’s disease, Alzheimer’s disease, epilepsy, and autism.


Related Links:

NimbleGen
Roche


Print article

Channels

Genomics/Proteomics

view channel
Image: A dark field photomicrograph showing the spirochete bacterium Borrelia burgdorferi, the pathogen responsible for causing Lyme disease (Photo courtesy of the CDC).

Statins May Help Block Transmission of Lyme Disease

A recent study found that treatment with cholesterol-lowering statins reduced the number of Borrelia burgdorferi bacteria in rodents, which helped to block transmission of Lyme disease. Lyme disease... Read more

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.